NewGenIvf Group Limited (NIVF) 股票分析

公司概述

NewGenIvf Group Limited operates as an investment holding company dedicated to providing assisted reproductive services that facilitate fertility treatments for couples and individuals across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The firm functions within the Healthcare sector, specifically classified under the Medical Care Facilities industry, where its business model revolves around offering a comprehensive range of fertility treatment solutions, including in vitro fertilization. This entity manages a market capitalization of $1.21M while reporting trailing twelve-month revenue of $4.73M; the employee count is not disclosed in the available financial data. These valuation and revenue figures indicate a micro-cap positioning within the specialized fertility care market, suggesting the company operates on a relatively small scale compared to larger public healthcare conglomerates. The disparity between its modest market cap and its reported profitability metrics further highlights the unique structural characteristics of its financial presentation in the current market environment.

财务健康

The company reported a revenue of $4.73M over the trailing twelve months, alongside a net income of $9.88M and an EBITDA of $-10,538,352. The significant gap between the positive net income and the negative EBITDA reveals a complex cost structure where non-cash charges or specific accounting adjustments related to interest and taxes have allowed net income to remain positive despite substantial operating cash burn. The free cash flow stands at $-11,179,275, indicating that the company is currently consuming cash rather than generating it from its operations, which limits its immediate financial flexibility for capital expenditures or debt repayment without external financing. Margin analysis shows a gross margin of 20.2%, an operating margin of -349.1%, and a profit margin of 209.0%; the negative operating margin suggests that operating expenses are currently exceeding gross profits on a pre-tax basis, while the anomalously high profit margin reflects the impact of non-operating income or extraordinary gains relative to revenue. Regarding liquidity and leverage, the company holds $1.30M in cash against total debt of $4.87M, resulting in a debt-to-equity ratio of 18.74, which points to a leveraged balance sheet where liabilities significantly outweigh equity holdings. However, the current ratio of 3.12 indicates strong short-term liquidity, as current assets are more than three times current liabilities, providing a buffer against immediate obligations. Return on Equity is recorded at 79.4% while Return on Assets is -36.9%, revealing that management has generated substantial equity returns through leverage or other equity adjustments, yet the asset base itself is generating a negative return, likely due to the high cash burn rate impacting the overall efficiency of the asset portfolio.

估值评估

The trailing twelve-month P/E ratio is calculated at 0.06, while the forward P/E is 0.23; this substantial difference implies that the market expects a significant shift in earnings trajectory, as the forward metric accounts for future earnings projections that are currently valued much higher than historical performance. The price-to-book ratio is listed as 0.00, which indicates that the market is not valuing the company's assets at a premium over their book value, often seen in entities with intangible-heavy or specialized service models where traditional book value metrics may not fully capture enterprise value. Alternative valuation metrics such as the price-to-sales ratio of 0.26 and the unavailable EV/EBITDA provide context for valuation relative to top-line revenue, suggesting the company trades at a fraction of its sales volume compared to mature peers. The stock has experienced extreme price volatility within the past year, ranging from a 52-week low of $1.52 to a 52-week high of $1839.00. Given the 52-week high of $1839.00 and low of $1.52, the current price sits significantly below the high, reflecting the wide dispersion and speculative nature of the trading range typical for micro-cap healthcare stocks. The beta value is not available, which prevents a direct comparison of price volatility relative to the broader market, but the wide range between the 52-week high and low suggests high sensitivity to market sentiment and sector-specific news.

Growth & Income

The company has demonstrated revenue growth of 11.9% year over year, whereas earnings growth is listed as N/A due to the unique financial structure where net income does not correlate linearly with revenue in the traditional sense. This divergence implies that the company's earnings are driven by factors other than top-line expansion, such as non-operating income or specific accounting treatments that decouple profit from revenue growth rates. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, indicating a strategy of retaining all earnings to fund operations or future growth initiatives rather than providing income to investors. The overall growth and income profile is characterized by strong top-line expansion coupled with negative free cash flow and zero dividend distribution, creating a high-risk, high-reward scenario reliant on future operational turnaround to restore cash generation capabilities.